Subtype
Malignant Female Reproductive System Neoplasm
CI-CAN-00003157Explore in graph →
1,466 active trials11 approved drugs128 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003157Explore in graph →
Clinical trials
6,256 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (740)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04250766 | Diagnostic Performances of Preoperative Echo-guided Uterine Biopsy in the Management of Suspect Uterine Sarcoma Tumors (BIOPSAR)(BIOPSAR) | active not recruiting | N/A | 19 | Institut BergoniéOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT06639074 | Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial | recruiting | Phase 2 | 78 | Mayo ClinicOTHER | 1 | Oct 2, 2025 |
| clinicaltrials |
| NCT04512144 | Mindfulness in Endometrial and Cervical Cancer(MECCA) | recruiting | N/A | 120 | St. Louis UniversityOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT06861855 | Prognosis of METTL-14 in Endometrial Carcinoma | not yet recruiting | — | 50 | Assiut UniversityOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT04111978 | MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)(MATAO) | recruiting | Phase 3 | 540 | Swiss GO Trial GroupNETWORK | 3 | Sep 29, 2025 | clinicaltrials |
| NCT05990803 | A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Cervical Cancer and Other Gynecological Malignancies | recruiting | Phase 2 | 130 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT06619769 | eSense-Cancer: Adapting an Online Intervention for Sexual Health Concerns to Gynecologic Cancer(eSense-Cancer) | recruiting | N/A | 60 | University of British ColumbiaOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT05197881 | Daily Adaptive Radiation Therapy an Individualized Approach for Carcinoma of the Cervix(ARTIA-Cervix) | recruiting | N/A | 125 | Varian, a Siemens Healthineers CompanyINDUSTRY | 1 | Sep 23, 2025 | clinicaltrials |
| NCT05606133 | Circulating Human Papilloma Virus (HPV) DNA for the Screening and Surveillance of Gynecologic Cancers | recruiting | N/A | 100 | Northwell HealthOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT02628067 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | active not recruiting | Phase 2 | 1,609 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 22, 2025 | clinicaltrials |
| NCT07088731 | Clinical Study to Evaluate the Efficacy and Safety of Nab-Paclitaxel Combined With Cisplatin and Sintilimab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer | not yet recruiting | Phase 2 | 180 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT07186868 | QL706 + Chemo ± Bevacizumab in Anti-PD-(L)1-Resistant R/M Cervical Cancer | not yet recruiting | — | 25 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Sep 22, 2025 | clinicaltrials |
| NCT03029403 | Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer | active not recruiting | Phase 2 | 47 | University Health Network, TorontoOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT04763915 | Improving Care After Inherited Cancer Testing(IMPACT) | active not recruiting | N/A | 720 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT06451263 | Nudge to Gynecologic Oncology | active not recruiting | N/A | 20 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT07027046 | Application of da Vinci SP for Endometrial Cancer Surgical Staging | recruiting | — | 564 | National Cancer Institute, NaplesOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT06518746 | Gonadal Dysgenesis Tissue Cryopreservation for Fertility Preservation | recruiting | N/A | 50 | University of Colorado, DenverOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT06663553 | Comparing the Efficacy of TU-LESS and vNOTES for Hysterectomy of Enlarged Uterus | not yet recruiting | N/A | 210 | West China Second University HospitalOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT06731998 | Optimal Perioperative Pain Control in Minimally Invasive Abdominal Cancer Surgery(LapTAP) | recruiting | N/A | 48 | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)OTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT05133661 | SUCCESS - Feasibility of HPV Testing and Treatment of Pre-cancerous Cervical Cancer Lesions (HPV Study)(HPV) | active not recruiting | — | 17,602 | JhpiegoOTHER | 4 | Sep 17, 2025 | clinicaltrials |
| NCT05329532 | Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer(ModiFY) | recruiting | Phase 1 / Phase 2 | 168 | Scancell LtdINDUSTRY | 1 | Sep 17, 2025 | clinicaltrials |
| NCT06152731 | HRD Tests for Ovarian cancER(HERO) | recruiting | Phase 2 | 88 | Centre Francois BaclesseOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT06942286 | Primary HPV Self-Collection in Indonesia | enrolling by invitation | N/A | 8,000 | Dharmais National Cancer Center HospitalOTHER_GOV | 1 | Sep 17, 2025 | clinicaltrials |
| NCT07177534 | Prospective Validation Study of a Uterine Fibroid-Related Infertility Prediction Model | not yet recruiting | — | 7,084 | Tongji HospitalOTHER | 0 | Sep 17, 2025 | clinicaltrials |
| NCT07177716 | Efficacy and Safety of LB1410 Plus Lenvatinib With or Without LB4330 in Advanced Recurrent/Metastatic Cervical Cancer | not yet recruiting | Phase 2 / Phase 3 | 120 | L & L Bio Co., Ltd., Ningbo, ChinaINDUSTRY | 1 | Sep 17, 2025 | clinicaltrials |
| NCT04511988 | Using Liquid Biopsy in Newly Diagnosed Patients With High Grade Adenocarcinoma of Ovarian Origin, Fallopian Tubes or Primary Peritoneal(BOVARY CE) | active not recruiting | N/A | 20 | Institut de Cancérologie de LorraineOTHER | 1 | Sep 16, 2025 | clinicaltrials |
| NCT04794322 | Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer | recruiting | — | 250 | Massachusetts General HospitalOTHER | 1 | Sep 16, 2025 | clinicaltrials |
| NCT03958240 | Deciphering Mechanisms Underlying Cancer Immunogenicity(DECIDE) | recruiting | N/A | 1,100 | Institut Claudius RegaudOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT07172217 | The Efficacy and Safety RC48 Plus QL1706 in Second-Line Treatment of HER2-Expressing Recurrent CC | not yet recruiting | Phase 2 | 33 | Qilu Hospital of Shandong UniversityOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT07078682 | An Open-Label Study to Evaluate the Effect of Elix Cycle Balance & Elix Daily Harmony on Fibroid-related Symptoms | recruiting | N/A | 42 | Zenchi, Inc.INDUSTRY | 1 | Sep 12, 2025 | clinicaltrials |
| NCT07170982 | Fruquintinib Combined With Standard Chemotherapy Versus Standard Chemotherapy as First-line Treatment for Advanced pMMR Endometrial Cancer | not yet recruiting | Phase 2 | 128 | Sun Yat-sen UniversityOTHER | 1 | Sep 12, 2025 | clinicaltrials |
| NCT07171528 | Secondary Cytoreductive Surgery After Chemotherapy for Recurrent Epithelial Ovarian Cancer(KOV-02S) | recruiting | Phase 2 | 80 | National Cancer Center, KoreaOTHER_GOV | 1 | Sep 12, 2025 | clinicaltrials |
| NCT06709534 | An Individualized Online Home-Based Exercise Program for Improving Symptoms in Gynecologic Cancer Survivors | recruiting | N/A | 40 | Emory UniversityOTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT07055399 | Neoadjuvant Iparomlimab and Tuvonralimab Plus Chemotherapy-eclipse for Locally Advanced Cervical Cancer (NICE-CC)(NICE-CC) | recruiting | Phase 2 | 43 | Fujian Cancer HospitalOTHER_GOV | 1 | Sep 11, 2025 | clinicaltrials |
| NCT07168083 | Efficacy and Safety of Sacituzumab in Patients With OCCC After Immunotherapy Progression | not yet recruiting | — | 22 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Sep 11, 2025 | clinicaltrials |
| NCT05009082 | Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer | recruiting | Phase 3 | 970 | AGO Study GroupOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT04906993 | Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer | active not recruiting | Phase 3 | 443 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT05107674 | A Study of NX-1607 in Adults With Advanced Malignancies | recruiting | Phase 1 | 345 | Nurix Therapeutics, Inc.INDUSTRY | 2 | Sep 9, 2025 | clinicaltrials |
| NCT07160010 | Clinical Validation of Sophia Genetics Assay(COSMOS) | not yet recruiting | — | 248 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 0 | Sep 8, 2025 | clinicaltrials |
| NCT05462379 | Autologous Heterotopic Fresh Ovarian Graft in Woman With LACC Eligible for Pelvic Radiotherapy Treatment. | active not recruiting | Phase 1 / Phase 2 | 22 | MARILIA ALBANEZI BERTOLAZZIOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT06802198 | A Randomized Study Comparing Subtotal vs Total Hysterectomy Long Term Outcomes(STORY) | not yet recruiting | N/A | 500 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT07156253 | Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 110 | Hangzhou SynRx Therapeutics Biomedical Technology Co., LtdINDUSTRY | 1 | Sep 5, 2025 | clinicaltrials |
| NCT03180034 | Comparing One or Two Doses of the Human Papillomavirus Vaccine for the Prevention of Human Papillomavirus Infection, ESCUDDO Study(ESCUDDO) | active not recruiting | Phase 4 | 27,945 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2025 | clinicaltrials |
| NCT07153705 | OCS Products Based on Exosome Technology Were Applied in the Recurrence Monitoring Study After the Initial Treatment of Baseline CA125-negative Ovarian Cancer | not yet recruiting | — | 32 | Beihua KongOTHER | 0 | Sep 4, 2025 | clinicaltrials |
| NCT07153952 | RT for Adenocarcinoma/Adenosquamous Carcinoma | active not recruiting | Phase 1 / Phase 2 | 60 | Peking Union Medical College HospitalOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT04555226 | The Efficacy of Lymph Node Dissection for Stage IIICr of Cervical Cancer(CQGOG0103) | recruiting | N/A | 452 | Chongqing University Cancer HospitalOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT07148154 | Development of a Non-invasive IVD for Endometrial Cancer Screening on High-risk Populations | recruiting | — | 3,000 | MiMARK Diagnostics, S.L.INDUSTRY | 1 | Aug 29, 2025 | clinicaltrials |
| NCT03878849 | Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer | recruiting | Phase 2 | 40 | Allarity TherapeuticsINDUSTRY | 1 | Aug 28, 2025 | clinicaltrials |
| NCT05629065 | Pathways to Advance Targeted and Helpful Serious Illness Conversations (PATH-SIC)((PATH-SIC)) | active not recruiting | N/A | 800 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 28, 2025 | clinicaltrials |
| NCT07117877 | Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer | not yet recruiting | Phase 2 | 33 | Fudan UniversityOTHER | 1 | Aug 28, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Oct 2, 2025source: clinicaltrials